Smets EMA, Garssen B, Schuster-Uitterhoeve ALJ, de Haes JCJM: Fatigue in cancer patients.
2.
Watanabe S, Bruera E: Anorexia and cachexia, asthenia, and lethargy. Hem/Onc Clin N Am. 1996;10:189-206.
3.
Bruera E.MacDonald RN: Asthenia in patients with advanced cancer. J Pain Symptom Manage. 1988;3:9-14.
4.
Lehman J, De Lisa J, Warren C, et al: Cancer rehabilitation: Assessment of need, development and evaluation of a model care. Arch Phys Med Rehabil. 1978;59:410-419.
5.
Bruera E, Carrara S, Roca E, et al: Association between malnutrition and caloric in-take, emesis, psychological depression, glucose taste and tumor mass. Ca Treat Rep. 1984;68:873-876.
6.
Bruera E, Carrara S, Roca E, et al: Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite and activity in terminal cancer patients. Ca Treat Rep. 1985;70:295-297.
7.
Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Ca Treat Rep. 1985;69:751-754.
8.
Bruera E, Chadwick S, Brenneis C: Methylphenidate associated with narcotics for the treatment of cancer pain. Ca Treat Rep. 1987;71:120-127.
9.
Bruera E, Brenneis C, Michaud M, et al: Association between involuntary muscle function and asthenia, nutritional status, lean body mass, psychometric assessment and tumor mass in patients with advanced cancer. Proc Am Soc Clin Oncol. 1987;6:261.
10.
Most undertreated cancer-related syndrome? It may be fatigue, which is often mistaken for depression. Prim Care & Ca. 1997;12 (3):10.
11.
Morant R: Asthenia: An important symptom in cancer patients. Ca Treat Rep. 1996;22 (Suppl):117-122.
12.
Morant R: Asthenia in cancer patients: A double-edged inflammatory response against the tumor. J Palliat Care1991; 7 (22): 22-24.
Theologides A: Anorexins, asthenins and cachectins in cancer. Am J Med. 1986;81: 296-298.
15.
Warmolts JR, Re PK, Lewis RJ, Engel WK: Type II muscle fiber atrophy (II-atrophy): An early systemic effect of cancer. Neurology. 1975;2:374.
16.
Bruera E, Jackson F, Michaud M, et al: Muscle electrophysiology in patients with advanced breast cancer. J Natl Cancer Inst. 1988;80:282-286.
17.
Holroyde R, Axelrod RS, Skutchers CL, et al: Lactate metabolism in patients with metastatic colorectal cancer. Cancer Res. 1979;39:4900-4904.
18.
Morant R, Stiefel F, Radziwill A: Preliminary results of a study assessing asthenia and related phenomena in patients with advanced cancer. J Supp Care. 1993;1:101-107.
19.
Piper RF, Lindsey AM, Dodd MJ: Fatigue mechanisms in cancer patients: Developing nursing theory. Oncol Nurs. 1987; 14: 17-23.
20.
Alexander HR, Norton JA: Pathophysiology of cancer cachexia. In: Doyle D, Hanks G, MacDonald E, eds. Oxford Textbook of Palliative Medicine. London: Oxford University Press, 1993:316-329.
21.
Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med. 1987;316:379-385.
22.
Kayes JR: Depression and chronic fatigue in cancer patients. Primary Care. 1991;18: 327-339.
23.
Blesch K, Paice JA, Wickham R, et al: Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum. 1991;18: 81-87.
24.
Beck SA, Smith KS, Tisdale MJ: Anticachexic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991;51:6089-6093.
25.
Koretz R: Parenteral nutrition: Is it oncologically logical?J Clin Oncol. 1984;2: 534-538.
26.
Bruera E, MacMillan K, Hanson J, et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990; 66: 1279-1282.
27.
Bruera E, Roca E, Cedaro L, et al: Action of oral methylprednisolone in terminal cancer patients: A prospective randomized doubleblind study. Ca Treat Rep. 1985; 69: 751-754.
28.
Popiela T, Lucchi R, Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol. 1989; 25: 1823-1829.
